Search…

Yiling Pharmaceutical (002603.SZ): The clinical trial application for the innovative chemical drug "LB220-D08 Sustained-Release Tablets" has been accepted.

12/08/2026

According to a report from Zhitong Finance APP, Yiling Pharmaceutical (002603.SZ) announced that it has recently received the "Acceptance Notice" issued by the National Medical Products Administration, for the drug named: "LB220-D08 Extended-Release Tablet."

Latest

5 m ago

In July, Portugal's final coordinated CPI increased by 3.1% year-on-year.

5 m ago

Qingdao Bank (03866.HK): The appointment qualifications of independent non-executive director Zhang Shixing have been approved by the Qingdao Bureau of the National Financial Supervisory Administration.

5 m ago

Ningde Times established a holding company that includes AI software development business.

5 m ago

New Silk Road Holdings Group (00472.HK) issued a profit warning, expecting its interim net loss attributable to shareholders to narrow year-on-year to approximately HK$13.9 million to HK$17 million.

6 m ago

Obituary of Comrade Zhu Rongji, issued by the Central Committee of the Communist Party of China, the Standing Committee of the National People's Congress, the State Council, and the National Committee of the Chinese People's Political Consultative Conference.

See all latest